Affymetrix Sees 'Opportunity' for Diagnostics Business in Increased FDA Oversight of LDTs

An Affy official noted that several assays that run on its FDA-approved platform have received clearance in the past, a fact that may give it an edge, or at least a head start, in a more-regulated molecular diagnostics environment.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.